Clinical Trial Update: Azacitidine Combined With Venetoclax in Patients With Higher-risk Chronic Myelomonocytic Leukemia (AVENHIR) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating azacitidine in combination with venetoclax for higher-risk chronic myelomonocytic leukemia is active/not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelomonocytic Leukemia

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Venetoclax (venetoclax)

Snippet

Sponsor: Groupe Francophone des Myelodysplasies | Conditions: Chronic Myeloid Leukemia | Phase 2 | Status: ACTIVE_NOT_RECRUITING